409 studies found for:    "Waldenstrom macroglobulinemia"
Show Display Options
Rank Status Study
1 Unknown  Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia
Conditions: Waldenström Macroglobulinemia;   Lymphoplasmacytic Lymphoma;   Splenic Marginal Zone Lymphoma
Interventions: Drug: Chlorambucil;   Drug: Fludarabine
2 Completed Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia
Conditions: Lymphoplasmacytic Lymphoma;   Waldenstrom's Macroglobulinemia
Intervention: Drug: Campath-1H
3 Completed Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
Conditions: Waldenstrom's Macroglobulinemia;   Lymphoplasmacytic Lymphoma
Intervention: Drug: Bortezomib (Velcade)
4 Completed
Has Results
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
Conditions: Waldenstrom's Macroglobulinemia;   Lymphoplasmacytic Lymphoma
Interventions: Drug: Thalidomide;   Drug: Rituximab
5 Completed Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: BORTEZOMIB
6 Terminated Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: Epratuzumab (hLL2- anti-CD22 humanized antibody)
7 Not yet recruiting An Open-label, Phase 1b Study of ACP 196 in Subjects With Waldenström Macroglobulinemia
Condition: Waldenström Macroglobulinemia (WM)
Intervention: Drug: ACP-196
8 Recruiting Ibrutinib With Rituximab in Previously Treated Adults With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Interventions: Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab
9 Recruiting Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Conditions: B Cell Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Intervention: Drug: AVL-292
10 Recruiting Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Conditions: Cognitive/Functional Effects;   Fatigue;   Neurotoxicity;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Therapy-related Toxicity;   Waldenström Macroglobulinemia
Interventions: Drug: temsirolimus;   Biological: rituximab;   Drug: bortezomib;   Drug: dexamethasone;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
11 Terminated Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
Condition: Waldenström Macroglobulinemia
Interventions: Biological: ofatumumab;   Drug: bortezomib;   Other: laboratory biomarker analysis
12 Terminated Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Interventions: Drug: Thalidomide;   Drug: Lenalidomide;   Drug: Rituximab
13 Completed Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma;   Waldenstrom Macroglobulinemia
Intervention: Drug: MLN0128
14 Completed
Has Results
Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Perifosine
15 Active, not recruiting Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: Bortezomib;   Drug: Rituximab
16 Completed Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Condition: Waldenström Macroglobulinemia
Intervention: Biological: oblimersen sodium
17 Completed Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: Thalidomide
18 Active, not recruiting
Has Results
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinaemia
Intervention: Biological: Ofatumumab
19 Completed Sildenafil Citrate in Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Sildenafil citrate (Viagra)
20 Terminated
Has Results
DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: DT PACE + Rituxan

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years